Search - tctmd.com

Displaying 121 - 140 of 174

Sort: Relevancy | Date

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Daily News

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Michael O'Riordan

April 17, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Industry News

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

October 02, 2017

News Daily News

Air Pollution Tightly Tied to CV Disease, Chinese Study Confirms

Ashley Lyles

August 15, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

Michael O'Riordan

December 01, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

L.A. McKeown

August 11, 2016

News Daily News

Los Fibroateromas de Casquete Fino Podrían Explicar los Malos Resultados PCI de los Pacientes Diabéticos

Todd Neale

July 06, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

越来越多证据显示以肠促胰岛素类降糖药不会增加心衰风险

Michael O'Riordan

March 25, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

Advertisement

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Statins and Diabetes: Causal Link Reinforced in New Analysis

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Air Pollution Tightly Tied to CV Disease, Chinese Study Confirms

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

Los Fibroateromas de Casquete Fino Podrían Explicar los Malos Resultados PCI de los Pacientes Diabéticos

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

越来越多证据显示以肠促胰岛素类降糖药不会增加心衰风险

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content